1、Chu, Tian-Qing ; Ding, Hao; Garfield, David H. ; Gu, Ai-Qin,Pei, Jun ; Du#, Wei-Dong ; Han, Bao-Hui . Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Endostatin and Paclitaxel-Carboplatin Chemotherapy? A Retrospective Study. J Thorac Oncol,2012;7(12):1781-9
2、Bai H, Han B#. The Effectiveness of Erlotinib Against Brain Metastases in Non-Small-cell Lung Cancer Patients.. Am J Clin Oncol, 2012;
3、Wenting Wu, Huan Li, Huibo Wang, Xueying Zhao, Zhiqiang Gao, Rong Qiao, Wei Zhang, Ji Qian, Jiucun Wang, Hongyan Chen, Qingyi Wei, Baohui Han and Daru Lu#. Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients.. PLoS One, 2012; 7(3):e33200
4、Shaohua Gu, Qihan Wu, Xueying Zhao, Wenting Wu, Zhiqiang Gao, Xiaoming Tan, Ji Qian, Hongyan Chen, Yi Xie, Li Jin, Baohui Han#, Daru Lu. Association of CASP3 polymorphism with hematologic toxicity in advanced NSCLC patients treated with platinum-based chemotherapy. Cancer Sci, 2012;103(8):1451-9
5、Wei-feng Mao, Min-hua Shao, Pin-ting Gao, Ji Ma, Hui-juan Li, Gai-ling Li, Bao-hui Han and Chong-gang Yuan#. The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. Acta Pharmacologica Sinica, 2012;33(10):1311-8
6、Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; on behalf of the INFORM investigators. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol,2012;13(5):466-475
7、Gao Z, Han B#, Wang H, Shi C, Xiong L, Gu A. Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC. Oncol Lett,2012;3(5):1064-1068
8、 Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M.. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol,2012;8(3):232-43
9、Zhong R, Teng J, Han B#, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer.. Cancer Immunol Immunother, 2011;60(10):1497-502
10、Han B*, Gao G, Wu W, Gao Z, Zhao X, Li L, Qiao R, Chen H, Wei Q, Wu J, Lu D. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. . Lung Cancer,2011;72(2):238-43
11、Jiayuan Sun, David H Garfield, Bing Lam, Jingjing Yan, Aiqin Gu, Jie Shen and Baohui Han. The Value of Autofluorescence Bronchoscopy Combined with White Light Bronchoscopy Compared with White Light Alone in the Diagnosis of Intraepithelial Neoplasia and Invasive Lung Cancer: A Meta-Analysis.. J Thorac Oncol,2011;6(8):1336-44
12、Rong Li ,Jing Wu ,Meili Ma ,Jun Pei ,Yiyi Song ,Xueyan Zhang , Baohui Han#. Comparison of PG-SGA, SGA and body-compositionmeasurement in detecting malnutrition among newly diagnosedlung cancer patients in stage IIIB/IV and benign conditions. Med Oncol,2011;28(3):689-96
13、ZHIQIANG GAO, BAOHUI HAN#, JIE SHEN, AIQIN GU, DAJIANG QI, JINSU HUANG, CHUNLEI SHI,LIWEN XIONG, YIZHUO ZHAO, LIYAN JIANG, HUIMIN WANG and YURONG CHEN. ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer. Exp Ther Med,2011;2(5):811-815
14、Han#, Baohui MD, PhD; Xiu, Qingyu MD, PhD; Wang, Huimin MD; Shen, Jie MD; Gu, Aiqin MD; Luo, Yi MD; Bai, Chunxue MD, PhD; Guo, Shuliang MD; Liu, Wenchao MD; Zhuang, Zhixiang MD; Zhang, Yang MD, PhD; Zhao, Yizhuo MD; Jiang, Liyan MD, PhD; Zhou, Jianying MD; Jin, Xianqiao MD. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer . Journal of Thoracic Oncology,2011;6(6):1104-9
15、Peng H, Ma M, Han B#. Survival analysis of 1,742 patients with stage IVnon-small cell lung cancer. Zhongguo Fei Ai Za Zhi,2011;14(4):362-6
16、Gao Z, Han B#, Shen J, Gu A, Zhong H. Relations between RRM1 proteinexpression levels and effects of gemcitabine and cisplatin chemotherapy inadvanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi,2011;14(4):340-4
17、Shi C, Han B#, Gu A, Xiong L, Shen J. Role of Erlotinib 100 mg/d in theTreatment of ?Advanced Adenocarcinoma Lung Cancer Failed to PreviousChemotherapy.. Zhongguo Fei Ai Za Zhi,2011;20;14(6):529-533
18、Chun-Lei Shi, Xue-Yan Zhang, Bao-Hui Han#, Wei-Zhong He, Jie Shen and Tian-Qing Chu. A clinicopathological study of resected non-small cell lung cancers 2 cm or less in diameter: a prognostic assessment.. Med Oncol,2011;28(4):1441-6
19、Qian J, Shen J, Bai H, Han B#. The clinical analysis of paclitaxel at two doselevels plus carboplatin as the first-line treatment in advanced non-small celllung cancer. Zhongguo Fei Ai Za Zhi,2011;14(4):323-8
20、Dai Y, Han B#. Research advance on non-small cell lung carcinoma withneuroendocrine differentiation. Zhongguo Fei Ai Za Zhi,2011;14(2):165-9
21、Xueyan Zhang, Baohui Han#, Jinsu Huang, Biqiang Zheng, Qin Geng, Fahad Aziz3and Qianggang Dong. Prognostic Significance of OCT4 Expression in Adenocarcinoma of the Lung. Jpn J Clin Oncol,2010;40(10):961-6
22、Jiayuan Sun, Jian Zhang, Heng Zhao, Jie Shen, Aiqin Gu & Baohui Han. Role of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of bronchogenic carcinoma: Experience of a single institution in China . Thoracic Cancer, 2010;
23、Gu Ping, Wang Hui-Min, Wang Wei-Min and Han Bao-Hui. Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population . Med Oncol, 2010;28(2):578-83
24、Bo Jin, Ai-Mi Huang, Run-Bo Zhong and Bao-Hui Han . The Value of Tumor Markers in Evaluating Chemotherapy Response and Prognosis in Chinese Patients with Advanced Non-Small Cell Lung Cancer. Chemother,2010; 56(6):417-423
25、ZHANG X, FENG J, SHA H, HUANG J, HAN B#. Correlations between IGF-IRexpression and clinicopathological factors and prognosis in patients with lungadenocarcinoma. Zhongguo Fei Ai Za Zhi,2010;13(12):1113-7
26、Xin Y, Han B#, Lou J, Wu J, Niu Y. Diagnostic value of bone metabolic markersICTP and BAP in lung cancer patients with bone metastases. Zhongguo Fei Ai Za Zhi,2010;13(10):947-53
27、 Zhong H, Han B#. Paclitaxel blocks immunologic escape through up-regulatingTAP-1, TAP-2 and eliminatiing Treg cells in 3LL-bearing mice. Zhongguo Fei Ai Za Zhi,2010;13(10):937-41
|
